AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00001296
Drug: interferon-gamma
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03510975
Drug: desmopressin melt form 120 μg
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: desmopressin melt form 120 μg (Minirin, Ferring International center, Switzerland) once daily before going to bed
Trial: NCT01183013
Drug: Pioglitazone 15 mg
RxNorm normalized name: pioglitazone 15 MG
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone Capsules 15 mg once daily for 30 weeks followed by Pioglitazone Capsules 30 mg once daily for up to 54 weeks
Trial: NCT01183013
Drug: Pioglitazone 45 mg
RxNorm normalized name: pioglitazone 45 MG
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone Capsules 30 mg once daily for 6 weeks followed by Pioglitazone Capsules 45 mg once daily for up to 78 weeks
Trial: NCT01183013
Drug: Pioglitazone 30 mg
RxNorm normalized name: pioglitazone 30 MG
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone Capsules 30 mg once daily for up to 84 weeks
Trial: NCT01183013
Drug: Linagliptin 5mg / Pioglitazone 45 mg FDC
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linagliptin 5mg low dose / Pioglitazone 30 mg Tablets once daily for 6 weeks followed by Linagliptin 5mg low dose / Pioglitazone 45 mg FDC Tablets once daily for up to 78 weeks
Trial: NCT01183013
Drug: Linagliptin 5mg / Pioglitazone 30 mg FDC
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 84 weeks
Trial: NCT01183013
Drug: Linagliptin 5mg
RxNorm normalized name: LINAGLIPTIN 5MG TAB
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Linagliptin 5mg Tablets low dose once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
Trial: NCT02252302
Drug: Salbutamol inhalation
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study participants will be exposed to 400ug of salbutamol prior to entering the air pollution chamber.
Trial: NCT03114085
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 500 mg po qd, d1-d21, every 21 days for one cycle
Trial: NCT01183013
Drug: Linagliptin 5mg / Pioglitazone 15 mg FDC
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linagliptin 5mg low dose / Pioglitazone 15 mg FDC Tablets once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
Trial: NCT01189370
Drug: sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose Level:~1. 400mg twice daily, continuous.~2. 600mg twice daily, days 1-5 of each week.~3. 800mg twice daily, days 1-5 of each week.
Trial: NCT02402465
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive fluticasone nasal spray
Trial: NCT03263715
Drug: Tocilizumab Prefilled Syringe [Actemra]
RxNorm normalized name: tocilizumab Prefilled Syringe [Actemra]
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly administration of Tocilizumab 162 mg subcutaneous from Baseline to Week 16.
Trial: NCT04098393
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine (25mg/m2/ day) administered on days -6, -5, -4, -3, and -2.
Trial: NCT04098393
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan (70mg/m2/day) administered on days -6 and -5.
Trial: NCT04098393
Drug: Antithymocyte globulin (ATG)
RxNorm normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG will be given based on a dynamic nomogram based on the patient's absolute lymphocyte count at the start of conditioning and can result in 2 or 3 days of ATG administration.
Trial: NCT04098393
Drug: Busulfan 0.8 mg/kg
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan 0.8 mg/kg every 6 hours x 10 doses, with dose adjustments made according to PK levels.
Trial: NCT00991029
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Loading dose of 600mg followed by 75 milligrams, oral, one tablet daily for 89 days
Trial: NCT02720081
Drug: Montelukast 10 mg
RxNorm normalized name: montelukast 10 MG
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg tablet administered orally, QD, at bedtime
Trial: NCT02720081
Drug: Albuterol/Salbutamol 90 mcg - 100 mcg per inhalation
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 or 2 inhalations 4 times a day (QID) as needed (PRN) as a Rescue Medication
Trial: NCT02845375
Drug: Sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sugammadex will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
Trial: NCT02845375
Drug: Neostigmine
RxNorm normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neostigmine will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
Trial: NCT00825734
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose Level 1 - Sorafenib PO BID (200mg) Dose Level -1 - Sorafenib PO BID (200mg) Dose Level 1a - Sorafenib PO BID (400mg)
Trial: NCT00825734
Drug: Ixabepilone
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose Level 1 - Ixabepilone IV every 21 days (40mg/m\^2) Dose Level -1 - Ixabepilone IV every 21 days (32mg/m\^2) Dose Level 1a - Ixabepilone IV every 21 days (32mg/m\^2)
Trial: NCT02954796
Drug: SGN-CD352A
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On the first day of each 28-day cycle, SGN-CD352A will be given IV. The dose of SGN-CD352A is different in each cohort of the study, with the lowest dose in Cohort -1 (4 mcg/kg) and the highest in Cohort 6 (65 mcg/kg). Patients can only be enrolled into a higher dose level arm if lower doses have proven safe.
Trial: NCT03654729
Drug: Calmangafodipir (2 µmol/kg)
RxNorm normalized name: mangafodipir
DrugBank: Calmangafodipir (DB18398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solution in 20 mL single dose glass vials
Trial: NCT03654729
Drug: Calmangafodipir (5 µmol/kg)
RxNorm normalized name: mangafodipir
DrugBank: Calmangafodipir (DB18398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solution in 20 mL single dose glass vials
Trial: NCT01013831
Drug: Erlotinib Hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01695005
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00335517
Drug: DepoDur
RxNorm normalized name: Depodur
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An epidural catheter will be placed under direct vision at the conclusion of surgery. The catheter will be advanced at least 4cm to L1 level prior to injection. Two mililiters of air will be injected through the catheter to ensure patency. Aspiration will be done to ensure no intradural injections. Then the undiluted (1 or 1.5 cc) DepoDur will be injected.
Trial: NCT00052078
Drug: Sertraline (SRT)
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants were treated with sertraline.
Trial: NCT00387972
Drug: denagliptin (GW823093)
RxNorm normalized name: Linagliptin
DrugBank: Denagliptin (DB16134)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00588146
Drug: Pegylated Interferon Alpha2b
RxNorm normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly subcutaneous injection of 1 microgram/kg/week
Trial: NCT00302536
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus
Trial: NCT03845517
Drug: PF-06700841 15 mg
RxNorm normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06700841 15 mg
Trial: NCT03845517
Drug: PF-06700841 30 mg
RxNorm normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06700841 30 mg
Trial: NCT03845517
Drug: PF-06700841 45 mg
RxNorm normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06700841 45 mg
Trial: NCT00645320
Drug: Ziprasidone
RxNorm normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ziprasidone tablets 40 or 80 mg twice daily with meals for 3 months. Doses were flexible based on investigator's discretion.
Trial: NCT05560945
Drug: 0.32% Sodium Fluoride Dentifrice Toothpaste
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Toothpaste
Trial: NCT01498445
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Starting Dose: 100 mg by mouth once daily of a 28 day cycle.
Trial: NCT01498445
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting Dose (less intensive group) Schedule A: 10 mg/m2 by vein daily for 10 days of a 28 day cycle.
Trial: NCT01498445
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting Dose (more intensive group) Schedule B: 20 mg/m2 by vein daily for 10 days of a 28 day cycle.
Trial: NCT01061775
Drug: Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 20 weeks.
Trial: NCT00463801
Drug: Daptomycin
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01058291
Drug: KW-6500
RxNorm normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twelve weeks subcutaneous injection of 1 to 6 mg for the OFF state
Trial: NCT03272347
Drug: Islatravir
RxNorm normalized name: Islatravir
DrugBank: Islatravir (DB15653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Islatravir at 0.25 mg, 0.75 mg or 2.25 mg is orally administered QD in capsule form for up to 52 weeks. After Week 60 a selected open label dose may be administered.
Trial: NCT03272347
Drug: Placebo to Islatravir
DrugBank: Islatravir (DB15653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to islatravir is orally administered QD in capsule form for up to 52 weeks
Trial: NCT03272347
Drug: Doravirine
RxNorm normalized name: Doravirine
DrugBank: Doravirine (DB12301)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Doravirine 100 mg is orally administered QD in tablet form for up to 144 weeks
Trial: NCT03272347
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine 300 mg is orally administered QD in tablet form for up to 52 weeks
Trial: NCT03272347
Drug: Placebo to Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo to Lamivudine is orally administered QD in tablet form for up to 52 weeks
Trial: NCT03272347
Drug: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
RxNorm normalized name: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed dose combination of 100 mg doravirine + 300 mg lamivudine + 300 mg tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 144 weeks.
Trial: NCT03272347
Drug: Doravirine/Islatravir
DrugBank: Doravirine (DB12301)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fixed dose combination of islatravir 0.75 mg/doravirine 100 mg orally administered QD in tablet form for 48 weeks
Trial: NCT00703677
Drug: Lithium
RxNorm normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will receive lithium. The dosage will be titrated over a 5-week period and then continued for an additional 6 months.
Trial: NCT02774044
Drug: Survanta
RxNorm normalized name: Survanta
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00702260
Drug: Ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg capsule
Trial: NCT01450514
Drug: Pipamperone
RxNorm normalized name: pipamperone
DrugBank: Pipamperone (DB09286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg PIP once daily per os on top of continued stable treatment with RIS or PAL
Trial: NCT01775787
Drug: Nicotine with Tobacco Flavor and Tobacco & Menthol Flavor
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects randomized to either Tobacco Flavor group for 7-10 days than crossed over to Tobacco \& Menthol Flavor for 7-10 days or Tobacco \& Menthol Flavor group for 7-10 days than crossed over to Tobacco Flavor for 7-10 days
Trial: NCT01535469
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole 800mg orally daily for 2 weeks, then 400mg daily for 8 weeks
Trial: NCT00578279
Drug: dehydrated alcohol
RxNorm normalized name: DEHYDRATED ALCOHOL
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subject randomized to 10ml or 20ml of dehydrated alcohol one time during the EUS-CPN procedure
Trial: NCT01018745
Drug: BMS-907351 (XL184)
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, Oral, 25, 50, 75, 100, 125 and 175 mg, Once daily, Until disease progression or unacceptable toxicity became apparent
Trial: NCT03636308
Drug: nanoparticle albumin-bound paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 of each 14 day cycle or day 1 and 8 of 21 day cycle.
Trial: NCT02915172
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase 1 Dose Escalation: Starting dose of Lenvatinib 10 mg by mouth once daily of a 21 day cycle.~Phase 2 Dose Expansion: Starting dose of Lenvatinib is maximum tolerated dose from Phase 1.
Trial: NCT00256932
Drug: alvimopan
RxNorm normalized name: Alvimopan
DrugBank: Alvimopan (DB06274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg
Trial: NCT02748057
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01990573
Drug: 0.3mg/kg IV methadone HCl
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group I will receive 0.3mg/kg IV methadone HCl
Trial: NCT04445090
Drug: BI 1569912
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1569912
Trial: NCT01476267
Drug: dalcetrapib
RxNorm normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral radiolabeled dose
Trial: NCT00905632
Drug: BI 207127 middle dose +SOC
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 207127 middle dose tid + SOC
Trial: NCT00004276
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00905632
Drug: BI 207127 high dose+SOC
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 207127 high dose tid +SOC
Trial: NCT00905632
Drug: BI 207127 low dose + SOC
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 207127 low dose tid + SOC
Trial: NCT00677313
Drug: metreleptin
RxNorm normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: metreleptin injection
Trial: NCT04232644
Drug: Crushed d-amphetamine sulfate IR tablets
RxNorm normalized name: amphetamine / dextroamphetamine
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: crushed d-amphetamine sulfate IR 6 x 5 mg tablets
Trial: NCT00758498
Drug: armodafinil
RxNorm normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/day orally, once daily in the morning for 3 days
Trial: NCT00161434
Drug: valacyclovir
RxNorm normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 gram daily for 8 weeks
Trial: NCT00758498
Drug: armodafinil
RxNorm normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg/day orally, once daily in the morning for 3 days
Trial: NCT00308516
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combined Modality Treatment:~fluorouracil 225mg/m2 IV continuous infusion days 1-42~Systemic Treatment:~5-fluorouracil 400 mg/m2 bolus 5-fluorouracil 2400 mg/m2 over 46 hours days 1 and 15
Trial: NCT00308516
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combined Modality Treatment:~bevacizumab 5mg/kg IV infusion days 1, 15, and 29~Systemic Treatment:~bevacizumab 5 mg/kg days 1 and 15
Trial: NCT00308516
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Systemic Treatment:~oxaliplatin 85 mg/m2 days 1 and 15
Trial: NCT03782987
Drug: BI 730357
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg BI 730357 tablet orally on Day 1
Trial: NCT03782987
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mL of 10 mg/ mL Itraconazole oral solution in treatment period 2 only (T). Itraconazole was administered once daily for 12 days from Day -3 to Day 9.
Trial: NCT02982889
Drug: LIQ865A bupivacaine formulation
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single subcutaneous injection in medial calf
Trial: NCT02982889
Drug: LIQ865B bupivacaine formulation
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single subcutaneous injection in medial calf
Trial: NCT02982889
Drug: 0.5% bupivacaine hydrochoride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single subcutaneous injection
Trial: NCT03636308
Drug: S1
RxNorm normalized name: LS11
DrugBank: LS11 (DB05918)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 is orally administered (BSA\<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA\>1.5m2, 60mg bid) on day 1-7 of each 14 day cycle.
Trial: NCT03636308
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine is given at 1000mg/m2 intravenously on d1 and 8 of each 21 day cycle.
Trial: NCT00005959
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00005959
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01945047
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Bolus infusion Ketamine Hydrochloride 0.50 mg/mL over 40 minutes
Trial: NCT01945047
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bolus infusion of Midazolam Hydrochloride 1 mg/mL over 40 minutes
Trial: NCT02065401
Drug: Deferitazole (disodium salt, granule)
RxNorm normalized name: flavodic acid, disodium salt
DrugBank: Deferitazole (DB13120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 1500 mg administered on Day 1
Trial: NCT02065401
Drug: Deferitazole (disodium salt, tablet)
RxNorm normalized name: flavodic acid, disodium salt
DrugBank: Deferitazole (DB13120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 1500 mg administered on Day 1
Trial: NCT02065401
Drug: Deferitazole (magnesium hydroxide salt)
RxNorm normalized name: Magnesium Hydroxide
DrugBank: Deferitazole (DB13120)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of 2400 mg administered on Day 1